Maxion Therapeutics is a biotechnology company that uses its revolutionary KnotBody® technology to create first-in-class and best-in-class protein therapeutics for treating previously untreatable ion channel and GPCR-driven diseases. They have a mission to develop innovative therapies that improve the lives of patients suffering from chronic pain.
Location: United Kingdom, England, South Hams
Total raised: $18.48M
Investors 2
| Date | Name | Website |
| 10.03.2023 | BGF Ventur... | bgf.co.uk |
| - | Life Arc V... | lifearcven... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.04.2023 | - | $2.48M | - |
| 19.02.2023 | Series A | $16M | - |
Mentions in press and media 8
| Date | Title | Description |
| 01.02.2024 | Maxion Therapeutics Welcomes Dr Arndt Schottelius as New CEO | 1 February 2024 – Cambridge, UK – Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announced today that Dr Arndt Schottelius has been... |
| 25.01.2024 | Six new investments, portfolio progress and an expanding investment team | Clare Terlouw, Head of LifeArc Ventures, said: “Our portfolio of investments expanded during the year and despite challenging financing conditions in the sector we were pleased to invest in six new companies and to continue to support our e... |
| 20.10.2023 | 3 LifeArc Ventures’ portfolio companies celebrated in new report on most innovative life science businesses in UK | With the UK setting its sights on becoming a global life sciences superpower, it has created an environment where scientists are able to push the boundaries of research to create breakthrough science. Many companies and start-ups have rise... |
| 19.04.2023 | Maxion Therapeutics awarded £2 million Innovate UK funding to develop ion channel antibodies for “hard-to-treat” autoimmune diseases | Cambridge, UK – 19 April 2023 – Biotechnology company Maxion Therapeutics (‘Maxion’) today announced it has been awarded a prestigious GBP £2 million grant from innovate uij as part of its Biomedical Catalyst 2022 Round 2: lndustrvd ied R&... |
| 19.04.2023 | Maxion Therapeutics awarded £2 million Innovate UK funding to develop ion channel antibodies for autoimmune diseases | John McCafferty, CEO and Aneesh Karatt Vellatt, CSO, Maxion Therapeutics • Targets critical unmet clinical need in autoimmunity, affecting ~300 million globally • Awarded as part of £25 million Innovate UK Biomedical Catalyst fund We're del... |
| 16.02.2023 | UK-based Maxion Therapeutics raises USD 16 million in Series A | Cambridge, UK-based biotechnology company advancing biologic medicines, Maxion Therapeutics, raised USD 16 million in Series A funding. The Series A round took place on February 15, 2023. LifeArc Ventures, the investment arm of LifeArc, led... |
| 15.02.2023 | Maxion Therapeutics Raises $16M in Series A Funding | Maxiom Therapeutics, a Cambridge, UK-based biotechnology company advancing biologic medicines, raised $16M in Series A funding. The round was led by LifeArc Ventures, Monograph Capital and BGF. As part of the financing, Dr Sohaib Mir (Senio... |
| - | Maxion Therapeutics | “Maxion Therapeutics | We are using our revolutionary KnotBody® technology to create first-in-class and best-in-class protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases.” |